Adcendo ApS to Share Insights on Clinical ADC Developments at 2025 AACR Annual Meeting

Adcendo ApS Upcoming Presentation at AACR 2025

Adcendo ApS, a forward-thinking biotechnology firm based in Copenhagen, is gearing up to present valuable research on its advanced antibody-drug conjugates (ADCs), ADCE-T02 and ADCE-D01, at the prestigious American Association for Cancer Research (AACR) Annual Meeting in Chicago, Illinois. This exciting event will occur from April 25 to April 30, 2025, presenting Adcendo with a platform to showcase groundbreaking findings in oncology.

Highlighting the ADCs

ADCE-T02

ADCE-T02 is a pioneering ADC designed as a topoisomerase-1 (Topo-1) inhibitor that specifically targets Tissue Factor (TF). This particular target has been clinically validated and is found to be overexpressed in various solid tumors while being minimally present in normal tissues. The innovative structure of ADCE-T02 includes a next-generation antibody coupled to an exatecan-based payload, utilizing a well-established linker-payload technology.

Preclinical trials have demonstrated that ADCE-T02 exhibits robust anti-tumor properties across a wide spectrum of solid tumor models while maintaining a good tolerability profile in non-human primate studies. With no signs of toxicity observed from earlier-generation TF ADCs, ADCE-T02 is currently undergoing a phase 1 clinical trial aimed at advanced solid tumors in the United States and Australia, with recruitment actively underway in Australia and U.S. enrollment set to start soon.

ADCE-D01

On the other hand, ADCE-D01 represents another groundbreaking innovation as a first-in-class ADC targeting the urokinase plasminogen activator receptor-associated protein (uPARAP). This target is known for its overexpression in mesenchymal tumors, such as sarcomas, while showing limited presence in healthy tissues. ADCE-D01 utilizes a topoisomerase-1 inhibitor payload, P-1021, and its preclinical evaluations have indicated significant anti-tumor effectiveness, particularly in models of soft tissue sarcoma.

Similar to ADCE-T02, preclinical safety assessments have shown favorable tolerability and no significant target-specific toxicities in non-human primate models. ADCE-D01 is also in phase 1 clinical trials for advanced soft tissue sarcomas in the U.S. and is currently under regulatory scrutiny in the European Union.

Leadership's Vision

Dr. Dominik Mumberg, Chief Scientific Officer at Adcendo, expressed enthusiasm regarding the promising data emerging from the preclinical evaluations of both ADCs. He emphasized the strong anti-tumor activity and acceptable tolerability profiles noted across numerous epithelial and mesenchymal tumor models. The team at Adcendo is looking forward to advancing both ADC programs through their phase 1 clinical trials, enhanced by the positive feedback expected from the scientific community during the AACR Annual Meeting.

Conference Presentation Details

On April 29th, Adcendo will present posters detailing the efficacy of ADCE-T02 and ADCE-D01. The sessions are scheduled from 9:00 AM to 12:00 PM CT, with a focus on innovative approaches to antibody-drug conjugates. The presentations will provide insight into the unique methodologies utilized in developing these ADCs, the preclinical results achieved, and the promising pathways toward future clinical applications.

Understanding Antibody-Drug Conjugates (ADCs)

ADCs are a strategic innovation in cancer treatment, combining the precise targeting abilities of antibodies with the potent effects of cytotoxic drugs. This dual-action mechanism allows for highly selective targeting of cancerous tissues while minimizing damage to healthy cells, thereby enhancing therapeutic efficacy and reducing side effects in patients.

About Adcendo ApS

Adcendo ApS is a clinical-stage biotechnology company focused on developing revolutionary ADCs for cancers with significant unmet medical needs. The company operates from Copenhagen, Denmark, along with a presence in Boston, Massachusetts. With a considerable background in advancing ADCs to approval, the Adcendo team aims to integrate innovative targets and optimized strategies in crafting next-generation cancer therapies. For more information about Adcendo and their exciting pipeline, visit www.adcendo.com or connect with them on LinkedIn.